Study Summary
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor (CAR) will be infused back to patients with refractory /relapsed B cell malignancies, including lymphoma and leukemia. The patients will be monitored after infusion of anti-CD19 CAR-transduced T cells for safety,adverse events, persistence of anti-CD19 CAR-transduced T cells and treatment efficacy.
Want to learn more about this trial?
Request More InfoInterventions
Drugs and anti-CD19 CAR transduced T cellsCOMBINATION_PRODUCT
Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 (IV) will be infused over 30 minutes.
Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300-500mg/m2 IV will be infused over 60 minutes followed by fludarabine.
Biological: Anti-CD19-CAR T cells On day 0, cells will be infused intravenously IV over 20 - 30 minutes.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Department of Hematology, Dongguan People's Hospital | Dongguan | Guangdong | China |
| Department of Hematology, the First People's Hospital of Foshan | Foshan | Guangdong | China |
| Department of Hematology, Guangzhou First People's Hospital | Guangzhou | Guangdong | China |
| Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University | Guangzhou | Guangdong | China |
| Department of Hematology,the Second Affiliated Hospital of Guangzhou Medical University | Guangzhou | Guangdong | China |